Fat Distribution May Influence Bone Strength in Adolescence

This article originally appeared here.
Share this content:
Fat Distribution May Influence Bone Strength in Adolescence
Fat Distribution May Influence Bone Strength in Adolescence

MONDAY, Nov. 20, 2017 (HealthDay News) -- Visceral adipose tissue (VAT) in girls and central adiposity in boys play a role in the acquisition of bone strength during adolescence, according to a study published online Oct. 30 in the Journal of Bone and Mineral Research.

Natalie A. Glass, Ph.D., from University of Iowa Hospitals & Clinics in Iowa City, and colleagues evaluated the longitudinal relationships among VAT, subcutaneous adipose tissue (SAT), and peripheral bone strength during adolescence among 182 girls and 167 boys aged 11 to 19 years.

The researchers found that fat mass and SAT were positively associated with strength-strain index (SSI), an indicator of peripheral bone strength, before but not after adjustment for lean mass in girls. In contrast, fat mass and SAT were negatively associated with radial SSI both before and after adjustment for lean mass in boys. Negative associations, in full models, were limited to VAT in girls and included radial and tibial SSI, but for boys, there were no significant associations between VAT and SSI at the radius or tibia.

"These results that show a negative relationship between peripheral bone strength and VAT in girls, but greater total and central adiposity in boys, suggest these factors play a role in adequate acquisition of bone strength during adolescence," conclude the authors.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

Lab  Companion Tests Perform Similarly for Oncology Analytes

Lab + Companion Tests Perform Similarly for Oncology ...

Findings based on comparison of tests to diagnose oncology-related genetic variants

Ulixertinib Is Active in Patients With Advanced Solid Tumors

Ulixertinib Is Active in Patients With Advanced Solid ...

Responses occurred in patients with NRAS-, BRAF V600-, non-V600 BRAF-mutant solid tumors

Doctors Must Report on at Least 1 Patient, 1 Measure for MACRA

Doctors Must Report on at Least 1 Patient, ...

To avoid Medicare payment penalty in 2019, clinicians must report by Dec. 31, submit by Feb. 28

is free, fast, and customized just for you!

Already a member?

Sign In Now »